Click here for Besponsa®▼ (inotuzumab ozogamicin) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
In a retrospective analysis of the long term data from INO-VATE study; of the patients who received at least one dose of study drug (BESPONSA n=164 vs SC n=143), BESPONSA reduced hospitalisation times when compared with standard chemotherapy
Hospitalisation for both groups was mainly for treatment of underlying disease and toxicity including haematological toxicity and infection1
Overall, 136 of 164 (82.9%) BESPONSA patients and 135 of 143 (94.4%) SC patients experienced at least one hospitalisation1.
BESPONSA patients were observed for a mean of 85.0 days vs 45.2 for SC up to a total of 13,946 vs 6463 days, respectively1.
*Treatment of underlying disease includes hospitalisations for scheduled treatment related to ALL or study participation, relapse and preparation for HSCT.
ALL, acute lymphoblastic leukaemia; HSCT, haematopoietic stem cell transplantation; IRR, incidence rate ratio; SC, standard chemotherapy.
Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival
Hear Professor David Marks discuss the INO-VATE study including MRD negativity, long term survival and reducing risks of veno-occlusive disease
Download the Fast Facts Guide holding the key information for BESPONSA including mode of action, INO-VATE study design, INO-VATE results; efficacy and safety profile
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020